Nabriva Therapeutics plc announced that it agreed to an extension of its exclusive agreement with subsidiaries of Merck & Co. Inc., Kenilworth, N.J., USA (“Merck”), known as MSD outside the United States and Canada, to promote and distribute SIVEXTRO® (tedizolid phosphate) in the United States through December 31, 2026. SIVEXTRO is an oxazolidinone-class antibacterial indicated in adults and pediatric patients 12 years of age and older for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by certain susceptible Gram-positive microorganisms.

Nabriva has been marketing and distributing SIVEXTRO in the United States and certain of its territories as part of an exclusive agreement executed in July 2020 with Merck. Under the initial term of the agreement, Nabriva was solely responsible for marketing, sales, and distribution of SIVEXTRO in the United States through December 31, 2023. The amendment extends the agreement to December 31, 2026. The term of the agreement can be further extended by an additional three-year period, subject to mutual agreement.